Published by Global Banking & Finance Review®
Posted on February 25, 2026
2 min readLast updated: April 2, 2026
Add as preferred source on GoogleHaleon said Q4 organic revenue rose 2.1%, slowing from 3.4%, as a delayed flu season hit respiratory-health sales in North America and CEE. For 2026 it guides 3–5% organic growth, under the 4.4% market view.
Feb 25 (Reuters) - British consumer healthcare group Haleon forecast a 3% to 5% growth in 2026 organic revenue, below its medium-term forecast after weak consumer confidence in the United States, its largest market, weighed on sales.
The Sensodyne maker's organic revenue grew 2.1% over the three months through December, compared with 3.4% in the prior quarter, particularly weighed down by the performance in its respiratory health business.
A mild cold and flu season in North America and in Central and Eastern Europe hurt sales of respiratory products, compounding the impact of weak U.S. spending and rising competition that has pushed shoppers toward cheaper alternatives, especially in the company’s struggling Smokers’ Health range.
The company, which was spun off from GSK in 2022, said it is targeting an annualised gross cost savings of between 175 million pounds and 200 million pounds over the next two years.
"While the consumer environment remains challenging near-term, we are even more focused on driving category growth and increasing our market outperformance,” said Chief Executive Officer Brian McNamara in a statement.
Despite the sluggish growth outlook, Haleon announced 500 million pounds in share buybacks for 2026, matching its 2025 program, betting that cost cuts and margin improvements will offset tepid sales growth to deliver "high single digit" profit growth.
For 2026, the company expects organic revenue to grow between 3% and 5%, compared with market expectations of 4.4% growth, according to a company-compiled poll.
(Reporting by Raechel Thankam Job in Bengaluru; Editing by Rashmi Aich and Louise Heavens)
Haleon reported slower fourth-quarter organic revenue growth as a delayed flu season hurt respiratory-health sales. The update also outlines a 2026 organic growth outlook of 3–5%.
A weaker, delayed flu season reduced demand for respiratory products, especially in North America and Central and Eastern Europe, contributing to the slowdown in Q4 growth.
Haleon expects 2026 organic revenue growth of 3–5%, which is below the 4.4% growth anticipated by the market consensus.
Explore more articles in the Finance category
